Russian Vaccine Trial Faces Scrutiny

26 scientists have questioned the reliability of the data supporting Russia’s “Sputnik-V” COVID-19 vaccine.

They noted in an open letter that the Phase I/II trial results data from Moscow’s Gamaleya Institute published in The Lancet last week showed multiple participants reporting identical antibody levels, Reuters reportsThe authors found that "highly unlikely."

The Gamaleya Institute insists the results were authentic, accurate, and passed muster with reviewers.

Meanwhile: More details emerged on the suspected adverse reaction
 that spurred AstraZeneca to pause its COVID-19 vaccine trial.

The volunteer is believed to have a rare but serious spinal inflammatory disorder called transverse myelitis. She’s recovering and could be discharged today, STAT reports.

AstraZeneca said it still expects to learn by the end of 2020 the vaccine works, provided it gets the green light to resume the trials soon, according to Reuters.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top